Phase II, Open Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma

  • Cook, Mark (Principal Investigator)

Project Details

Short titlePhase II, Open Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma
StatusFinished
Effective start/end date30/04/0931/12/12

Funding

  • Queen Elizabeth Hospital Birmingham